Table 2.
Prevalence of patients meeting the criteria for metabolic syndrome in tirzepatide-treated patients by weight loss category (< 5%, > 5% to ≤ 10%, > 10% to ≤ 15%, > 15% to ≤ 20%, or > 20%)
| Metabolic syndrome risk factors | Weight Loss < 5% | Weight Loss > 5% to ≤ 10% | Weight Loss > 10% to ≤ 15% | Weight Loss > 15% to ≤ 20% | Weight Loss > 20% | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Primary Endpoint | Baseline | Primary Endpoint | Baseline | Primary Endpoint | Baseline | Primary Endpoint | Baseline | Primary Endpoint | |
| SURPASS-1 monotherapy, N | 85 | 100 | 57 | 34 | 25 | |||||
| ≥ 3 Risk Factors | 56 (65.9) | 50 (58.8) | 74 (74.0) | 57 (57.0) | 41 (71.9) | 19 (33.3) | 25 (73.5) | 12 (35.3) | 20 (80.0) | 5 (20.0) |
| WC > 102 cm (M), > 89 cm (F) | 57 (67.1) | 53 (62.4) | 69 (69.0) | 52 (52.0) | 35 (61.4) | 24 (42.1) | 24 (70.6) | 16 (47.1) | 19 (76.0) | 11 (44.0) |
| FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 85 (100.0) | 73 (85.9) | 100 (100.0) | 86 (86.0) | 57 (100.0) | 38 (66.7) | 34 (100.0) | 20 (58.8) | 25 (100.0) | 10 (40.0) |
| SBP > 130 mmHg or DBP > 85 mmHg | 47 (55.3) | 36 (42.4) | 38 (38.0) | 34 (34.0) | 27 (47.4) | 14 (24.6) | 19 (55.9) | 9 (26.5) | 8 (32.0) | 2 (8.0) |
| Triglycerides > 150 mg/dL | 38 (44.7) | 28 (32.9) | 55 (55.0) | 41 (41.0) | 30 (52.6) | 15 (26.3) | 14 (41.2) | 5 (14.7) | 12 (48.0) | 2 (8.0) |
| HDL < 40 mg/dL (M), < 50 mg/dL (F) | 40 (47.1) | 40 (47.1) | 58 (58.0) | 51 (51.0) | 33 (57.9) | 27 (47.4) | 20 (58.8) | 19 (55.9) | 17 (68.0) | 13 (52.0) |
| SURPASS-2 add-on to MET vs SEMA 1 mg, N | 268 | 327 | 269 | 187 | 139 | |||||
| ≥ 3 Risk Factors | 227 (84.7) | 203 (75.7) | 272 (83.2) | 192 (58.7) | 227 (84.4) | 108 (40.1) | 157 (84.0) | 55 (29.4) | 121 (87.1) | 28 (20.1) |
| WC > 102 cm (M), > 89 cm (F) | 222 (82.8) | 208 (77.6) | 268 (82.0) | 224 (68.5) | 224 (83.3) | 162 (60.2) | 158 (84.5) | 96 (51.3) | 124 (89.2) | 59 (42.4) |
| FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 268 (100.0) | 254 (94.8) | 327 (100.0) | 273 (83.5) | 269 (100.0) | 180 (66.9) | 187 (100.0) | 89 (47.6) | 139 (100.0) | 46 (33.1) |
| SBP > 130 mmHg or DBP > 85 mmHg | 160 (59.7) | 145 (54.1) | 191 (58.4) | 139 (42.5) | 149 (55.4) | 85 (31.6) | 100 (53.5) | 50 (26.7) | 79 (56.8) | 32 (23.0) |
| Triglycerides > 150 mg/dL | 145 (54.1) | 130 (48.5) | 189 (57.8) | 130 (39.8) | 151 (56.1) | 83 (30.9) | 98 (52.4) | 41 (21.9) | 64 (46.0) | 27 (19.4) |
| HDL < 40 mg/dL (M), < 50 mg/dL (F) | 148 (55.2) | 126 (47.0) | 177 (54.1) | 151 (46.2) | 159 (59.1) | 109 (40.5) | 110 (58.8) | 89 (47.6) | 80 (57.6) | 53 (38.1) |
| SURPASS-3 add-on to MET ± SGLT2i vs iDeg, N | 210 | 207 | 229 | 128 | 117 | |||||
| ≥ 3 Risk Factors | 174 (82.9) | 163 (77.6) | 171 (82.6) | 124 (59.9) | 195 (85.2) | 109 (47.6) | 108 (84.4) | 47 (36.7) | 95 (81.2) | 25 (21.4) |
| WC > 102 cm (M), > 89 cm (F) | 181 (86.2) | 171 (81.4) | 171 (82.6) | 134 (64.7) | 187 (81.7) | 135 (59.0) | 108 (84.4) | 66 (51.6) | 108 (92.3) | 49 (41.9) |
| FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 210 (100.0) | 205 (97.6) | 207 (100.0) | 181 (87.4) | 229 (100.0) | 182 (79.5) | 128 (100.0) | 82 (64.1) | 117 (100.0) | 50 (42.7) |
| SBP > 130 mmHg or DBP > 85 mmHg | 121 (57.6) | 107 (51.0) | 125 (60.4) | 97 (46.9) | 155 (67.7) | 81 (35.4) | 71 (55.5) | 39 (30.5) | 66 (56.4) | 28 (23.9) |
| Triglycerides > 150 mg/dL | 120 (57.1) | 120 (57.1) | 109 (52.7) | 81 (39.1) | 121 (52.8) | 65 (28.4) | 75 (58.6) | 32 (25.0) | 59 (50.4) | 14 (12.0) |
| HDL < 40 mg/dL (M), < 50 mg/dL (F) | 106 (50.5) | 103 (49.0) | 117 (56.5) | 90 (43.5) | 121 (52.8) | 90 (39.3) | 79 (61.7) | 56 (43.8) | 64 (54.7) | 39 (33.3) |
| SURPASS-4 ± MET ± SGLT2i ± SU vs iGlar, N | 212 | 186 | 218 | 115 | 92 | |||||
| ≥ 3 Risk Factors | 184 (86.8) | 168 (79.2) | 151 (81.2) | 110 (59.1) | 185 (84.9) | 110 (50.5) | 102 (88.7) | 49 (42.6) | 84 (91.3) | 26 (28.3) |
| WC > 102 cm (M), > 89 cm (F) | 177 (83.5) | 170 (80.2) | 142 (76.3) | 107 (57.5) | 175 (80.3) | 117 (53.7) | 95 (82.6) | 64 (55.7) | 86 (93.5) | 37 (40.2) |
| FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 212 (100.0) | 206 (97.2) | 186 (100.0) | 167 (89.8) | 218 (100.0) | 165 (75.7) | 115 (100.0) | 68 (59.1) | 92 (100.0) | 41 (44.6) |
| SBP > 130 mmHg or DBP > 85 mmHg | 141 (66.5) | 130 (61.3) | 113 (60.8) | 84 (45.2 | 149 (68.3) | 110 (50.5) | 73 (63.5) | 67 (58.3) | 52 (56.5) | 36 (39.1) |
| Triglycerides > 150 mg/dL | 122 (57.5) | 96 (45.3) | 113 (60.8) | 77 (41.4) | 111 (50.9) | 70 (32.1) | 64 (55.7) | 36 (31.3) | 41 (44.6) | 17 (18.5) |
| HDL < 40 mg/dL (M), < 50 mg/dL (F) | 124 (58.5) | 119 (56.1) | 110 (59.1) | 87 (46.8) | 131 (60.1) | 96 (44.0) | 78 (67.8) | 47 (40.9) | 63 (68.5) | 35 (38.0) |
| SURPASS-5 add-on to insulin glargine ± MET vs PBO, N | 110 | 79 | 57 | 43 | 19 | |||||
| ≥ 3 Risk Factors | 83 (75.5) | 78 (70.9) | 65 (82.3) | 44 (55.7) | 47 (82.5) | 22 (38.6) | 31 (72.1) | 10 (23.3) | 17 (89.5) | 5 (26.3) |
| WC > 102 cm (M), > 89 cm (F) | 96 (87.3) | 93 (84.5) | 67 (84.8) | 60 (75.9) | 48 (84.2) | 41 (71.9) | 32 (74.4) | 19 (44.2) | 17 (89.5) | 11 (57.9) |
| FSG ≥ 100 mg/dL or HbA1c ≥ 5.7% | 110 (100.0) | 98 (89.1) | 79 (100.0) | 56 (70.9) | 57 (100.0) | 35 (61.4) | 43 (100.0) | 15 (34.9) | 19 (100.0) | 2 (10.5) |
| SBP > 130 mmHg or DBP > 85 mmHg | 77 (70.0) | 72 (65.5) | 55 (69.6) | 40 (50.6) | 43 (75.4) | 15 (26.3) | 31 (72.1) | 13 (30.2) | 14 (73.7) | 5 (26.3) |
| Triglycerides > 150 mg/dL | 44 (40.0) | 34 (30.9) | 40 (50.6) | 24 (30.4) | 24 (42.1) | 13 (22.8) | 17 (39.5) | 6 (14.0) | 12 (63.2) | 4 (21.1) |
| HDL < 40 mg/dL (M), < 50 mg/dL (F) | 49 (44.5) | 48 (43.6) | 43 (54.4) | 37 (46.8) | 25 (43.9) | 20 (35.1) | 14 (32.6) | 14 (32.6) | 10 (52.6) | 7 (36.8) |
Data are n (%) at baseline and at the primary endpoint of 40 weeks (SURPASS-1, SURPASS-2 and SURPASS-5) or 52 weeks (SURPASS-3, SURPASS-4) in patients on-treatment compliant to study drug (patients taking ≥ 75% of assigned doses)
DBP: diastolic blood pressure; F: female; FSG: fasting serum glucose; HbA1c: glycated hemoglobin; HDL: high-density lipoprotein; iDeg: insulin degludec; iGlar: insulin glargine; M: male; MET: metformin; n: number of patients in the specified category; PBO: placebo; SBP: systolic blood pressure; SEMA: semaglutide; SGLT2i: sodium glucose cotransporter 2 inhibitor; SU: sulfonylurea; WC: waist circumference